Integrin alpha(4)beta(7) mediates human eosinophil interaction with MAdCAM-1, VCAM-1 and fibronectin

Garry Michael Walsh, F A Symon, A I Lazarovits, A J Wardlaw

Research output: Contribution to journalArticle

81 Citations (Scopus)

Abstract

We have investigated the contribution of integrin alpha(4) beta(7) to human peripheral blood eosinophil adhesive interactions. Immunofluorescence and flow cytometry demonstrated constitutive expression of alpha(4) beta(7) by eosinophils. Expression of alpha(4) beta(1) or alpha(4) beta(7) was not enhanced by eosinophil activation with platelet-activating factor (PAF). Expression of alpha(4) beta(7) was confirmed by immunoprecipitation of I-125-labelled lysates analysed by sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE). Approximately 20% of unstimulated eosinophils were adherent to L1-2 cells transfected with vascular cell adhesion molecule-1 (VCAM-1) cDNA, while very few resting eosinophils adhered to mouse mucosal adressin cell adhesion molecule-1 (MAdCAM-1) transfectants. Binding of unstimulated eosinophils to VCAM-1 transfectants was inhibited by HP1/2 (an antibody that blocks both alpha(4) beta(1) and alpha(4) beta(7) functions), but not Act-1, an alpha(4) beta(7) monoclonal antibody (mAb). PAF stimulation resulted in increased binding of eosinophils to MAdCAM-1 transfectants, which was inhibited by both HP1/2 and Act-1. In contrast, PAF did not enhance binding to VCAM-1 transfectants, although binding of PAF-stimulated eosinophils to VCAM-1 could be partially inhibited by Act-1. Stimulation of eosinophils with the beta(1)-activating mAb TS2/16 resulted in enhanced binding of eosinophils to both VCAM-1 and MAdCAM-1 transfectants. The increased binding was largely alpha 4 beta(7)-dependent. Unstimulated eosinophils bound to soluble recombinant human (rh)VCAM-1 and fibronectin (Fn), coated on 96-well plates in a dose-dependent manner. Binding was inhibited by HP1/2 and 4b4, an anti-beta(1) mAb, but not by Act-1. TS2/16 treatment increased adherent cell numbers and this enhanced binding was inhibited by Act-1. We have therefore confirmed that alpha(4) beta(1) is functionally active on unstimulated eosinophils. In contrast, PAF-induced enhancement of eosinophils binding to VCAM-1 or MAdCAM-1 was alpha(4) beta(7)-dependent. In addition, treatment with TS2/16 resulted in a alpha(4) beta(7)-dependent enhancement of eosinophil binding to VCAM-1, MAdCAM-1 and Fn. We therefore hypothesize that alpha(4) beta(7) may have an important role in eosinophil localization in diseases such as asthma and inflammatory bowel disease.

Original languageEnglish
Pages (from-to)112-119
Number of pages8
JournalImmunology
Volume89
Issue number1
Publication statusPublished - Sep 1996

Keywords

  • CELL-ADHESION MOLECULE-1
  • VASCULAR ENDOTHELIAL-CELLS
  • LATE ACTIVATION ANTIGEN-4
  • LEUKOCYTE ADHESION
  • MONOCLONAL-ANTIBODY
  • PLASMA FIBRONECTIN
  • CYTOPLASMIC DOMAIN
  • BETA-SUBUNIT
  • EXPRESSION
  • RECEPTOR

Cite this

Integrin alpha(4)beta(7) mediates human eosinophil interaction with MAdCAM-1, VCAM-1 and fibronectin. / Walsh, Garry Michael; Symon, F A ; Lazarovits, A I ; Wardlaw, A J .

In: Immunology, Vol. 89, No. 1, 09.1996, p. 112-119.

Research output: Contribution to journalArticle

Walsh, GM, Symon, FA, Lazarovits, AI & Wardlaw, AJ 1996, 'Integrin alpha(4)beta(7) mediates human eosinophil interaction with MAdCAM-1, VCAM-1 and fibronectin', Immunology, vol. 89, no. 1, pp. 112-119.
Walsh, Garry Michael ; Symon, F A ; Lazarovits, A I ; Wardlaw, A J . / Integrin alpha(4)beta(7) mediates human eosinophil interaction with MAdCAM-1, VCAM-1 and fibronectin. In: Immunology. 1996 ; Vol. 89, No. 1. pp. 112-119.
@article{0ab9febf8c304df585c29b7b6f775201,
title = "Integrin alpha(4)beta(7) mediates human eosinophil interaction with MAdCAM-1, VCAM-1 and fibronectin",
abstract = "We have investigated the contribution of integrin alpha(4) beta(7) to human peripheral blood eosinophil adhesive interactions. Immunofluorescence and flow cytometry demonstrated constitutive expression of alpha(4) beta(7) by eosinophils. Expression of alpha(4) beta(1) or alpha(4) beta(7) was not enhanced by eosinophil activation with platelet-activating factor (PAF). Expression of alpha(4) beta(7) was confirmed by immunoprecipitation of I-125-labelled lysates analysed by sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE). Approximately 20{\%} of unstimulated eosinophils were adherent to L1-2 cells transfected with vascular cell adhesion molecule-1 (VCAM-1) cDNA, while very few resting eosinophils adhered to mouse mucosal adressin cell adhesion molecule-1 (MAdCAM-1) transfectants. Binding of unstimulated eosinophils to VCAM-1 transfectants was inhibited by HP1/2 (an antibody that blocks both alpha(4) beta(1) and alpha(4) beta(7) functions), but not Act-1, an alpha(4) beta(7) monoclonal antibody (mAb). PAF stimulation resulted in increased binding of eosinophils to MAdCAM-1 transfectants, which was inhibited by both HP1/2 and Act-1. In contrast, PAF did not enhance binding to VCAM-1 transfectants, although binding of PAF-stimulated eosinophils to VCAM-1 could be partially inhibited by Act-1. Stimulation of eosinophils with the beta(1)-activating mAb TS2/16 resulted in enhanced binding of eosinophils to both VCAM-1 and MAdCAM-1 transfectants. The increased binding was largely alpha 4 beta(7)-dependent. Unstimulated eosinophils bound to soluble recombinant human (rh)VCAM-1 and fibronectin (Fn), coated on 96-well plates in a dose-dependent manner. Binding was inhibited by HP1/2 and 4b4, an anti-beta(1) mAb, but not by Act-1. TS2/16 treatment increased adherent cell numbers and this enhanced binding was inhibited by Act-1. We have therefore confirmed that alpha(4) beta(1) is functionally active on unstimulated eosinophils. In contrast, PAF-induced enhancement of eosinophils binding to VCAM-1 or MAdCAM-1 was alpha(4) beta(7)-dependent. In addition, treatment with TS2/16 resulted in a alpha(4) beta(7)-dependent enhancement of eosinophil binding to VCAM-1, MAdCAM-1 and Fn. We therefore hypothesize that alpha(4) beta(7) may have an important role in eosinophil localization in diseases such as asthma and inflammatory bowel disease.",
keywords = "CELL-ADHESION MOLECULE-1, VASCULAR ENDOTHELIAL-CELLS, LATE ACTIVATION ANTIGEN-4, LEUKOCYTE ADHESION, MONOCLONAL-ANTIBODY, PLASMA FIBRONECTIN, CYTOPLASMIC DOMAIN, BETA-SUBUNIT, EXPRESSION, RECEPTOR",
author = "Walsh, {Garry Michael} and Symon, {F A} and Lazarovits, {A I} and Wardlaw, {A J}",
year = "1996",
month = "9",
language = "English",
volume = "89",
pages = "112--119",
journal = "Immunology",
issn = "0019-2805",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Integrin alpha(4)beta(7) mediates human eosinophil interaction with MAdCAM-1, VCAM-1 and fibronectin

AU - Walsh, Garry Michael

AU - Symon, F A

AU - Lazarovits, A I

AU - Wardlaw, A J

PY - 1996/9

Y1 - 1996/9

N2 - We have investigated the contribution of integrin alpha(4) beta(7) to human peripheral blood eosinophil adhesive interactions. Immunofluorescence and flow cytometry demonstrated constitutive expression of alpha(4) beta(7) by eosinophils. Expression of alpha(4) beta(1) or alpha(4) beta(7) was not enhanced by eosinophil activation with platelet-activating factor (PAF). Expression of alpha(4) beta(7) was confirmed by immunoprecipitation of I-125-labelled lysates analysed by sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE). Approximately 20% of unstimulated eosinophils were adherent to L1-2 cells transfected with vascular cell adhesion molecule-1 (VCAM-1) cDNA, while very few resting eosinophils adhered to mouse mucosal adressin cell adhesion molecule-1 (MAdCAM-1) transfectants. Binding of unstimulated eosinophils to VCAM-1 transfectants was inhibited by HP1/2 (an antibody that blocks both alpha(4) beta(1) and alpha(4) beta(7) functions), but not Act-1, an alpha(4) beta(7) monoclonal antibody (mAb). PAF stimulation resulted in increased binding of eosinophils to MAdCAM-1 transfectants, which was inhibited by both HP1/2 and Act-1. In contrast, PAF did not enhance binding to VCAM-1 transfectants, although binding of PAF-stimulated eosinophils to VCAM-1 could be partially inhibited by Act-1. Stimulation of eosinophils with the beta(1)-activating mAb TS2/16 resulted in enhanced binding of eosinophils to both VCAM-1 and MAdCAM-1 transfectants. The increased binding was largely alpha 4 beta(7)-dependent. Unstimulated eosinophils bound to soluble recombinant human (rh)VCAM-1 and fibronectin (Fn), coated on 96-well plates in a dose-dependent manner. Binding was inhibited by HP1/2 and 4b4, an anti-beta(1) mAb, but not by Act-1. TS2/16 treatment increased adherent cell numbers and this enhanced binding was inhibited by Act-1. We have therefore confirmed that alpha(4) beta(1) is functionally active on unstimulated eosinophils. In contrast, PAF-induced enhancement of eosinophils binding to VCAM-1 or MAdCAM-1 was alpha(4) beta(7)-dependent. In addition, treatment with TS2/16 resulted in a alpha(4) beta(7)-dependent enhancement of eosinophil binding to VCAM-1, MAdCAM-1 and Fn. We therefore hypothesize that alpha(4) beta(7) may have an important role in eosinophil localization in diseases such as asthma and inflammatory bowel disease.

AB - We have investigated the contribution of integrin alpha(4) beta(7) to human peripheral blood eosinophil adhesive interactions. Immunofluorescence and flow cytometry demonstrated constitutive expression of alpha(4) beta(7) by eosinophils. Expression of alpha(4) beta(1) or alpha(4) beta(7) was not enhanced by eosinophil activation with platelet-activating factor (PAF). Expression of alpha(4) beta(7) was confirmed by immunoprecipitation of I-125-labelled lysates analysed by sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE). Approximately 20% of unstimulated eosinophils were adherent to L1-2 cells transfected with vascular cell adhesion molecule-1 (VCAM-1) cDNA, while very few resting eosinophils adhered to mouse mucosal adressin cell adhesion molecule-1 (MAdCAM-1) transfectants. Binding of unstimulated eosinophils to VCAM-1 transfectants was inhibited by HP1/2 (an antibody that blocks both alpha(4) beta(1) and alpha(4) beta(7) functions), but not Act-1, an alpha(4) beta(7) monoclonal antibody (mAb). PAF stimulation resulted in increased binding of eosinophils to MAdCAM-1 transfectants, which was inhibited by both HP1/2 and Act-1. In contrast, PAF did not enhance binding to VCAM-1 transfectants, although binding of PAF-stimulated eosinophils to VCAM-1 could be partially inhibited by Act-1. Stimulation of eosinophils with the beta(1)-activating mAb TS2/16 resulted in enhanced binding of eosinophils to both VCAM-1 and MAdCAM-1 transfectants. The increased binding was largely alpha 4 beta(7)-dependent. Unstimulated eosinophils bound to soluble recombinant human (rh)VCAM-1 and fibronectin (Fn), coated on 96-well plates in a dose-dependent manner. Binding was inhibited by HP1/2 and 4b4, an anti-beta(1) mAb, but not by Act-1. TS2/16 treatment increased adherent cell numbers and this enhanced binding was inhibited by Act-1. We have therefore confirmed that alpha(4) beta(1) is functionally active on unstimulated eosinophils. In contrast, PAF-induced enhancement of eosinophils binding to VCAM-1 or MAdCAM-1 was alpha(4) beta(7)-dependent. In addition, treatment with TS2/16 resulted in a alpha(4) beta(7)-dependent enhancement of eosinophil binding to VCAM-1, MAdCAM-1 and Fn. We therefore hypothesize that alpha(4) beta(7) may have an important role in eosinophil localization in diseases such as asthma and inflammatory bowel disease.

KW - CELL-ADHESION MOLECULE-1

KW - VASCULAR ENDOTHELIAL-CELLS

KW - LATE ACTIVATION ANTIGEN-4

KW - LEUKOCYTE ADHESION

KW - MONOCLONAL-ANTIBODY

KW - PLASMA FIBRONECTIN

KW - CYTOPLASMIC DOMAIN

KW - BETA-SUBUNIT

KW - EXPRESSION

KW - RECEPTOR

M3 - Article

VL - 89

SP - 112

EP - 119

JO - Immunology

JF - Immunology

SN - 0019-2805

IS - 1

ER -